Benserazide

Subscribe to Selected New Research on Benserazide

174 relevant articles (19 outcomes, 29 trials/studies) found for this Bio-Agent

Description: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.

Also Known As:

DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Ro 4-4602; Seryltrihydroxy Benzylhydrazine; Benzylhydrazine, Seryltrihydroxy; Ro 4 4602; Ro 44602; Serazide; Seryltrihydroxybenzylhydrazine; DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrazines: 42

Benserazide: 174

madopar: 81

Experts

1.	Mühlau, G: 1 article (12/2004)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 04/01/1982 - "These findings are discussed with regard to the use of these drugs in the therapy of Parkinson's Disease, although the paucity of information about the physiological function of CRAO makes the significance of its inhibition by benserazide unclear." 11/01/2005 - "The bioavailability of levodopa between the levodopa/carbidioa (100/12.5) group and the levodopa/benserazide (100/25) group was studied in patients with Parkinson's disease by population PK study" 04/30/1988 - "An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease]" 01/01/1986 - "An open study was carried out in 60 elderly patients with Parkinson's disease to assess the efficacy and tolerance of long-term treatment with levodopa/benserazide combination therapy" 01/01/1986 - "Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy." Get all the results and reference details, order at left...
2.	Dyskinesias (Dyskinesia) 02/01/2008 - "Principle component analysis of DA and DA metabolite levels with dyskinesia scores after l-DOPA/benserazide (6/15 mg/kg) administration indicated a significant correlation only for DA, whereas DA metabolites did not show any significant correlation with the occurrence of dyskinetic behavior" 04/15/2007 - "When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone" 01/01/2006 - "Four other MPTP-monkeys received LD/benserazide plus CI-1041; only one of them developed mild dyskinesias at the end of the fourth week of treatment" 01/01/2006 - "Four MPTP-monkeys received LD/benserazide alone; they all developed dyskinesias" 06/01/2005 - "Each patient was examined by a standard oral levodopa/benserazide test, based on simultaneous serial measurements of plasma levodopa concentrations, finger-tapping motor effects and dyskinesia ratings, up to 4 hours after dosing" Get all the results and reference details, order at left...
3.	Parkinsonian Disorders (Parkinsonism) 04/03/1982 - "Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide." 01/01/1974 - "Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602." 03/01/1997 - "In animal study, there is a report of teratogenicity (bone abnormality) of l-dopa/benserazide in rabbits at doses of 30 mg/kg and 120 mg/kg. However, there have been several reports of uneventful delivery of normal children in patients with juvenile parkinsonism who had been treated with l-dopa/decarboxylase inhibitor (DCI) during pregnancy" 04/01/2007 - "On admission, his parkinsonism was well controlled by 400 mg/ day of levodopa/benserazide" 11/01/1999 - "We compared the kinetic-dynamic profile of a postprandial dose of levodopa-benserazide dispersible formulation to that of the standard form in eight patients with parkinsonism presenting delayed or irregular patterns of after-meal levodopa dose effects" Get all the results and reference details, order at left...
4.	Tremor (Tremors) 01/01/1995 - "Tremor amplitude improved by > 90% in 38% of atypical, 27% of PD and none of the ET patients after single-dose L-dopa/benserazide (300/75 mg), a response which was significantly different between the ET and PD groups" 01/01/1988 - "A 66 year-old woman presented with severe memory disorders followed several months later with tremor of Parkinsonian type of the right upper limb totally relieved by treatment with levodopa-benserazide" 06/01/1985 - "These symptoms were reduced by L-DOPA plus benserazide but the putative D1-receptor agonist SKF 38393-A did not affect tremor and increased the bradykinesia" 12/01/1996 - "Therapeutic trials showed that both the dystonia and tremor were improved by subcutaneous injection of apomorphine, the dystonia by trihexyphenidyle, and the tremor by carbamazepine and propranolol, but not by levodopa and benserazide" Get all the results and reference details, order at left...
5.	Hypokinesia (Bradykinesia) 02/01/1998 - "After taking a single dose of oral levodopa/benserazide (200mg/50mg), the patients with WMH showed significantly less improvement in bradykinesia score than those without WMH (25 +/- 4.1% vs 40 +/- 4.0%, P < 0.05), but the improvements in other symptoms were comparable between the two groups" 02/01/2001 - "With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints" 06/01/1996 - "He was treated with 600 mg of levodopa with benserazide and 22.5 mg of bromocriptine with mild to moderate improvement in his bradykinesia and rigidity" 06/01/1985 - "These symptoms were reduced by L-DOPA plus benserazide but the putative D1-receptor agonist SKF 38393-A did not affect tremor and increased the bradykinesia" 01/01/1978 - "The hypokinesia is reversed by the putative dopamine-receptor agonists apomorphine, ET-495 and CB-154 as well as by the amino acids L-Dopa and m-tyrosine when administered in combination with the peripheral decarboxylase inhibitor Ro 4-4602" Get all the results and reference details, order at left...
56 Diseases and 174 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	madopar
3.	Carbidopa (Lodosyn)
4.	Delayed-Action Preparations
5.	Propranolol (Inderal)
6.	Apomorphine
7.	cabergoline
8.	Carbamazepine (Tegretol)
9.	istradefylline
10.	5-Hydroxytryptophan (5 Hydroxytryptophan)
97 Drugs and Important Bio-Agents and 168 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Induced Hypothermia
3 Therapies and Procedures and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>